Latest Content

Within the arena of chronic nonmalignant pain, researchers explore barriers, facilitators, and strategies for opioid optimization services in community pharmacies.

Diyaben Patel, PharmD, discusses where artificial intelligence is genuinely transforming pharmacy practice.

Exploring retail pharmacy data, specifically among Walgreens locations, researchers assess the impact of closures in socially vulnerable areas.

Price transparency, direct-to-consumer, and digital fulfillment channels are reshaping how patients obtain medications.

Often operating in the shadows, LTC pharmacy is the backbone of medication management for aging and immunocompromised patients.

New case-control study finds that patients with type 2 diabetes and more severe depressive symptoms show higher cortisol, higher hemoglobin A1C, and lower insulin.

A new surveillance study shows pneumococcal vaccine shifts cut key antibiotic resistance for invasive pneumococcal disease.

Among US adults with and without chronic medical conditions, researchers examine social media use for health-related information.

West Nile virus cases rise early in 2026, with Arizona leading with 32 cases.

In-home pharmacist visits uncover medication risks, improve adherence and deprescribing, and help older adults stay safer at home.

In part 2 of our interview, Esmé Grewal, JD, discusses the key opportunities LTC pharmacies possess in assisting the aging population in medication management.

Atacicept-vymj is the first medication for immunoglobulin A nephropathy that targets both B cell activating factor and a proliferation-inducing ligand inhibitors.

Pharmacists are being asked to serve as the frontline correctors of medical misinformation, but the emotional labor and repetition are compounding the severe burnout crisis.

Through a secret shopper study, researchers assessed the process for obtaining GLP-1 therapy via the internet and the clinical engagement associated with the purchase.

Researchers assess the impact of various pneumococcal conjugate vaccines since the introduction of immunization programming.

CDC-led VISION interim data show 2025-2026 COVID-19 shots cut adult emergency room visits and hospitalizations.

Researchers explore how the prevalence, duration, and characteristics of post-COVID-19 symptoms varied by epidemic period.

Data show bone density and lean mass losses can be clinically meaningful, but case reports point to resistance training as effective countermeasures.

Esmé Grewal, JD, joins to discuss the evolution of aging populations in the US and how LTC pharmacies are designed to address older adults’ outcomes.

FDA staff review recommends against adding 7 peptides to the 503A bulk list, citing gaps in characterization, effectiveness, and safety data.

Among patients using corticosteroids during hospital stays, researchers assess patient-reported symptoms of long COVID during follow-up.

Pharmacists can drive change through education, engagement, legislation, and persistent efforts.

The filing acceptance marks a step toward lower-cost alternatives to Mounjaro and Zepbound.

The collaborative effort includes millions of dollars dedicated to cloud and artificial technology for a global antimicrobial resistance intelligence platform.

With the dual issue of pharmacy deserts and caregiver shortages across the US, technology is filling a much-needed gap for rural patient populations.

Updated charter shifts committee governance to the CDC director and drops fixed meeting schedules.

Episode 12 explores recent updates from the 2026 ADA Scientific Sessions, highlighting for pharmacists which technologies are making waves in the diabetes space right now.

New analyses from the MAESTRO program and real-world studies bolster the evidence base for the metabolic dysfunction-associated steatohepatitis therapy.

A new sibling-matched cohort study challenges earlier observational data, offering pharmacists evidence-based reassurance to share with pregnant patients.

In part 2 of our interview series with Lisa Lavin, she explored the capabilities of her company’s Home Health Hub and how it’s transforming health care access for rural populations.

Coadministering COVID-19 and influenza vaccines did not raise the 90-day risk of serious or clinically meaningful adverse events.